Safe Harbor
Statement
2
This presentation contains forward-looking statements which include, without
limitation,
statements regarding the completion of the proposed merger transaction
between Nuvelo, Inc.,
ARCA biopharma, Inc. and Dawn Acquisition Sub, Inc. the proposed
mergers anticipated
benefits, timing, progress and anticipated completion of the
companies clinical stage and
research programs, the timing of regulatory
approval, the potential benefits that patients may
experience from the use of the
companies clinical stage compounds, and the cash position of
the companies
following the merger, which statements are hereby identified as forward-looking
statements for purposes of the safe harbor provided by the Private Securities Litigation
Reform
Act of 1995. Such statements are based on the companies managements
current expectations
and involve risks and uncertainties. Actual results and
performance could differ materially from
those projected in the forward-looking
statements as a result of many factors, including, without
limitation, failure to
complete the proposed merger in a timely fashion, the risk that Nuvelos and
ARCAs business operations will not be integrated successfully; the companies
inabilities to
further identify, develop and achieve commercial success for products
and technologies; the risk
that the companies financial resources will be
insufficient to meet their business objectives;
uncertainties relating to drug
discovery and the regulatory approval process; clinical
development processes;
enrollment rates for patients in the companies clinical trials; changes in
relationships with strategic partners and dependence upon strategic partners for the
performance of critical activities under collaborative agreements; and the impact of competitive
products and technological changes. These and other factors are identified and
described in
more detail in Nuvelos filings with the SEC, including without
limitation Nuvelos quarterly report
on Form 10-Q for the quarter ended
September 30, 2008 and subsequent filings. Nuvelo and
ARCA disclaim any intent or
obligation to update these forward-looking statements.
|